These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1279326)

  • 1. Treatment of minimal residual disease in acute leukemia--focus on immunotherapeutic options.
    Simonsson B; Nilsson BI; Rowe JM
    Leukemia; 1992 Nov; 6 Suppl 4():124-34. PubMed ID: 1279326
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options.
    Simonsson B
    Leukemia; 1996 Jun; 10 Suppl 2():s44-5. PubMed ID: 8649052
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide.
    Rowe JM; Nilsson BI; Simonsson B
    Leuk Lymphoma; 1993 Nov; 11(5-6):321-9. PubMed ID: 7510190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent progress in the treatment of hematological malignancies. III. Acute leukemia--bone marrow transplantation].
    Masaoka T
    Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):789-91. PubMed ID: 2677177
    [No Abstract]   [Full Text] [Related]  

  • 5. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoregulation rather than immunosuppression for prevention and treatment of autoimmune disorders.
    Slavin S
    Transplant Proc; 1996 Dec; 28(6):3021-2. PubMed ID: 8962172
    [No Abstract]   [Full Text] [Related]  

  • 7. How do BMTs cure leukaemia? New directions.
    Prentice HG
    Bone Marrow Transplant; 1991; 7 Suppl 2():11-3. PubMed ID: 1878667
    [No Abstract]   [Full Text] [Related]  

  • 8. Bone marrow transplantation as immunotherapy.
    Sondel PM
    Wis Med J; 1983 Oct; 82(10):17-9. PubMed ID: 6359729
    [No Abstract]   [Full Text] [Related]  

  • 9. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of GM-CSF in bone marrow transplantation.
    Vose JM; Armitage JO
    Behring Inst Mitt; 1991 Dec; (90):39-43. PubMed ID: 1801689
    [No Abstract]   [Full Text] [Related]  

  • 11. Perspectives in the prevention and treatment of acute graft versus host disease.
    Herve P
    Bone Marrow Transplant; 1991; 7 Suppl 2():117-9. PubMed ID: 1715225
    [No Abstract]   [Full Text] [Related]  

  • 12. Trying to overcome residual disease after bone marrow transplantation for hematologic malignancies.
    Klingemann HG
    Leuk Lymphoma; 1992 Dec; 8(6):421-9. PubMed ID: 1284296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
    Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
    Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
    [No Abstract]   [Full Text] [Related]  

  • 15. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications.
    Ringdén OT; Le Blanc K; Remberger M
    Exp Hematol; 2005 May; 33(5):505-12. PubMed ID: 15850828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of graft-versus-host disease following allogeneic bone marrow transplantation by removal of T-cells].
    de Gast GC; Verdonck LF; van Kempen-Harteveld ML; Gerritsen H; Dekker AW
    Ned Tijdschr Geneeskd; 1986 May; 130(19):868-71. PubMed ID: 3520348
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy after bone marrow transplantation.
    Klingemann HG; Phillips GL
    Bone Marrow Transplant; 1991 Aug; 8(2):73-81. PubMed ID: 1718516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.
    Champlin R
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):687-98. PubMed ID: 2193019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.